Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K J O'Byrne

Showing results (1-10 of 91) with videos related to

Pageof 10
Sort By:
Anticancer Research|March 23, 2002
Matrix metalloproteinases and cancerG Cox, K J O'Byrne
Gynecologic Oncology|May 26, 2005
CA-125 criteria for response evaluation in ovarian cancerS Sundar, K J O'Byrne
Clinical Science (London, England : 1979)|April 17, 1999
The promise of improved drug deliveryK J O'Byrne, W P Steward
Lancet (London, England)|October 21, 2000
Evolution, immune response, and cancerK J O'Byrne, A G Dalgleish
Expert Opinion on Emerging Drugs|July 2, 2005
Tumour angiogenesis: a novel therapeutic target in patients with malignant diseaseK J O'Byrne, W P Steward
Anti-Cancer Drugs|January 1, 1996
Radiolabelled somatostatin analogue scintigraphy in oncologyK J O'Byrne, D N Carney
British Journal of Cancer|August 17, 2001
Chronic immune activation and inflammation as the cause of malignancyK J O'Byrne, A G Dalgleish
Lung Cancer (Amsterdam, Netherlands)|December 1, 1993
Somatostatin and the lungK J O'Byrne, D N Carney
Lancet (London, England)|July 28, 2001
Infection and cancerK J O'Byrne, A G Dalgleish
The Lancet. Oncology|March 21, 2002
Intramedullary spinal cord metastasisN Mortimer, D Hughes, K J O'Byrne
Pageof 10

Showing results (1-10 of 91) with videos related to

Sort By:
Pageof 10
Anticancer Research|March 23, 2002
Matrix metalloproteinases and cancerG Cox, K J O'Byrne
Gynecologic Oncology|May 26, 2005
CA-125 criteria for response evaluation in ovarian cancerS Sundar, K J O'Byrne
Clinical Science (London, England : 1979)|April 17, 1999
The promise of improved drug deliveryK J O'Byrne, W P Steward
Lancet (London, England)|October 21, 2000
Evolution, immune response, and cancerK J O'Byrne, A G Dalgleish
Expert Opinion on Emerging Drugs|July 2, 2005
Tumour angiogenesis: a novel therapeutic target in patients with malignant diseaseK J O'Byrne, W P Steward
Anti-Cancer Drugs|January 1, 1996
Radiolabelled somatostatin analogue scintigraphy in oncologyK J O'Byrne, D N Carney
British Journal of Cancer|August 17, 2001
Chronic immune activation and inflammation as the cause of malignancyK J O'Byrne, A G Dalgleish
Lung Cancer (Amsterdam, Netherlands)|December 1, 1993
Somatostatin and the lungK J O'Byrne, D N Carney
Lancet (London, England)|July 28, 2001
Infection and cancerK J O'Byrne, A G Dalgleish
The Lancet. Oncology|March 21, 2002
Intramedullary spinal cord metastasisN Mortimer, D Hughes, K J O'Byrne
Pageof 10